Gecacitinib
Phase 2Small molecule
Gecacitinib is one of 275 small molecule programs targeting Acute Graft Versus Host Disease. It is currently in Phase 2.
8
Indications
9
Total Trials
9
Active Trials
274
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 3
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Sitravatinib
MMirati Therapeutics Inc.
Phase 3
Gecacitinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelofibrosis2 trials
Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07471503·39 enrolled
Non-Small Cell Lung Cancer1 trial
Safety and Efficacy1 trial
Acute Graft Versus Host Disease1 trial
3 more indications
Lymphoma1 trial
Refractory1 trial
Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT07476872·33 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gecacitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details